IDOV-Immune Trial
Phase 1
78
about 1.8 years
18+
3 sites in MO, TX
About this study
This trial is testing IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. The goal is to determine the safety and best dose of this treatment by monitoring side effects and how it affects the body and immune system. Participants will receive a single IV infusion of IDOV-Immune and be closely monitored.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive IDOV-Immune (oncolytic vaccinia virus)
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
intravenous
Primary: Determination of the Maximum Tolerated Dose (MTD), Incidence of Dose-Limiting Toxicities (DLTs), Safety and Tolerability of IDOV-Immune by Dose Level
Secondary: Disease Control Rate (DCR), Duration of Response (DOR), Objective Response Rate (ORR), Overall Survival (OS), Pharmacodynamic and Biomarker Responses Following IDOV-Immune Administration, Pharmacokinetic Parameters of IDOV-Immune by Dose Level, Progression-Free Survival (PFS)
Endocrinology, Oncology